Literature DB >> 5548560

Copper kinetics in liver disease.

R A Smallwood, B McIlveen, V M Rosenoer, S Sherlock.   

Abstract

The plasma clearance and the liver uptake of intravenously administered (64)Cu were significantly impaired in four patients with Wilson's disease. These defects were unlikely to be simply expressions of the high liver copper concentration as the plasma clearance and hepatic uptake of (64)Cu were normal in four patients with primary biliary cirrhosis, in whom the liver copper concentration was raised to a degree comparable to that in Wilson's disease. The normal liver uptake and plasma clearance of (64)Cu in three patients with other forms of hepatocellular disease suggest that impaired liver cell function does not have a significant effect. The precise nature of the defect in copper transport in Wilson's disease remains to be elucidated; it is possible that delayed uptake of copper by the hepatic lysosomes may account for the toxic effects of the metal.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5548560      PMCID: PMC1411543          DOI: 10.1136/gut.12.2.139

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Studies with radioactive copper (64Cu and 67Cu) in relation to the natural history of Wilson's disease.

Authors:  S B Osborn; J M Walshe
Journal:  Lancet       Date:  1967-02-08       Impact factor: 79.321

2.  Demonstration of copper and acid phosphatase activity in hepatocyte lysosomes in experimental copper toxicity.

Authors:  S Goldfischer
Journal:  Nature       Date:  1967-07-01       Impact factor: 49.962

3.  Subcellular distribution and enzyme changes following subacute copper intoxication.

Authors:  M A Verity; J K Gambell; A R Reith; W J Brown
Journal:  Lab Invest       Date:  1967-04       Impact factor: 5.662

4.  The liver-thigh 64Cu ratio in Wilson's disease.

Authors:  A J Levi; H S Williams
Journal:  Clin Sci       Date:  1968-04       Impact factor: 6.124

5.  Use of whole-body counter to study body retention of radiocopper in Wilson's disease.

Authors:  K Hamamoto; W N Tauxe; L P Novak; N P Goldstein
Journal:  J Lab Clin Med       Date:  1968-11

6.  Prevention of Wilson's disease in asymptomatic patients.

Authors:  I Sternlieb; I H Scheinberg
Journal:  N Engl J Med       Date:  1968-02-15       Impact factor: 91.245

Review 7.  Copper metabolism.

Authors:  A Sass-Kortsak
Journal:  Adv Clin Chem       Date:  1965       Impact factor: 5.394

8.  Tissue copper determinations by neutron activation analysis.

Authors:  A P Todd; M E Thorpe; V M Rosenoer
Journal:  J Clin Pathol       Date:  1967-05       Impact factor: 3.411

9.  A method for the demonstration of copper under the electron microscope.

Authors:  P J Scheuer; M E Thorpe; P Marriott
Journal:  J Histochem Cytochem       Date:  1967-05       Impact factor: 2.479

10.  Studies on the pathogenesis of hepatolenticular degeneration. I. Acid phosphatase activity in copper-loaded rat livers.

Authors:  R R Lindquist
Journal:  Am J Pathol       Date:  1967-10       Impact factor: 4.307

View more
  6 in total

1.  Survey of copper granules in liver biopsy specimens from various liver abnormalities other than Wilson's disease and biliary diseases.

Authors:  H Miyamura; Y Nakanuma; N Kono
Journal:  Gastroenterol Jpn       Date:  1988-12

2.  Demonstration of an intracellular copper-binding protein by orcein staining in long-standing cholestatic liver diseases.

Authors:  M Salaspuro; P Sipponen
Journal:  Gut       Date:  1976-10       Impact factor: 23.059

3.  Autoimmune chronic active hepatitis in a family.

Authors:  S Hodges; A Lobo-Yeo; P Donaldson; M S Tanner; D Vergani
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

4.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

5.  Hepatic copper content is normal in early primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  K V Kowdley; T A Knox; M M Kaplan
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

6.  Hepatic copper in primary biliary cirrhosis: biliary excretion and response to penicillamine treatment.

Authors:  M P Salaspuro; P Pikkarainen; P Sipponen; E Vuori; T A Miettinen
Journal:  Gut       Date:  1981-11       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.